Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Not Confirmed
Not Confirmed
05-06 June, 2025
Not Confirmed
Not Confirmed
05-06 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Europ. Pharma Outsourc...Europ. Pharma Outsourcing
Industry Trade Show
Not Confirmed
05-06 June, 2025
Industry Trade Show
Not Confirmed
05-06 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
28 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-announces-first-clinical-data-from-ongoing-investigator-initiated-trial-of-yolt-101-an-in-vivo-base-editing-therapy-for-familial-hypercholesterolemia-302439382.html
25 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-positive-clinical-data-for-yolt-203-an-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1-ph1-302384408.html
22 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-to-initiate-a-clinical-trial-for-yolt-204-a-first-in-class-bone-marrow-targeted-in-vivo-gene-editing-therapy-for--thalassemia-302355739.html
21 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-successful-completion-of-dose-escalation-phase-in-phase-i-trial-of-yolt-201-for-attr-302337849.html
27 Aug 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/yoltech-sells-china-rights-cholesterol-gene-editing-therapy-salubris-29m
22 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/yoltech-therapeutics-administers-first-patient-dose-in-iit-of-yolt-203-the-worlds-first-in-vivo-gene-editing-therapy-for-ph1-302228388.html
ABOUT THIS PAGE